fashion -WSS

fashion

author：entertainment 2025-10-02 14:38:50 - browse：86

LONDON — AstraZeneca said on Monday that a new lung cancer treatment outperformed standard-of-care chemotherapy in a trial, but investors found the results less impressive than anticipated, sending company shares down in early trading.

Based on an interim analysis of a Phase 3 trial, the company said that the drug, datopotamab deruxtecan, led to improvement in progression-free survival in patients non-small cell lung cancer, a primary endpoint of the study. There was also a positive early trend on overall survival, with Susan Galbraith, AstraZeneca’s oncology leader, describing the results as “compelling evidence for the potential role” that the drug could play for patients.

But investors had been hoping for a clearer signal of benefit. Analysts noted that despite the success in progression-free survival, it was not described as a “clinically meaningful” improvement, which, as J.P. Morgan analysts wrote, “we believe the market would have liked to have seen.”

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Heart attack and stroke risk calculators need revising
Next article： Trans patients at the end of life deserve respect and dignity

hotspot

WSS

Medicare reduced heart disease by changing how it pays doctors

Lawmakers consider Medicare pay reforms for doctors

Impact of Dobbs ruling felt at reproductive medicine meeting

FDA gives detailed accounting of AI

Hospital at home shows how to bring innovation to health care

2023 STAT Wunderkinds: get to know the winners

entertainment

fashion

knowledge

Sports medicine is finally prioritizing gender equality

Republicans love RFK Jr. What's that tell us about health in 2024?

Continuity nursing helped my family in our darkest PICU moments

Study: Spinal cord stimulation helps patients with paralysis walk again

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Wegovy improves function in certain heart failure patients

Affirmative action in medical school literally saved lives

The EU Joint Clinical Assessment needs to live up to its promise

The cancer drug shortage isn’t new — and neither are the solutions

HHS leader on health, climate change and biopharma emissions

explore

Why health workers in Gaza are injured or die at high rates

Study: Spinal cord stimulation helps patients with paralysis walk again

DeSantis wants to import drugs. Biden’s FDA blasted his plan

Republicans love RFK Jr. What's that tell us about health in 2024?

Drugmakers bet big on mRNA for cancer. Why's Biden going in?

HHS leader on health, climate change and biopharma emissions

Wikipedia

knowledge

hotspot

leisure time